Larimar Therapeutics Inc (LRMR) - Total Liabilities
Based on the latest financial reports, Larimar Therapeutics Inc (LRMR) has total liabilities worth $50.48 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Larimar Therapeutics Inc (LRMR) equity growth momentum to track the company's year-over-year net asset growth rate.
Larimar Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Larimar Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See LRMR free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Larimar Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Larimar Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firma Oponiarska DĘBICA SA
WAR:DBC
|
Poland | zł883.16 Million |
|
Metrodata Electronics Tbk
JK:MTDL
|
Indonesia | Rp8.10 Trillion |
|
Beijing Bashi Media Co Ltd
SHG:600386
|
China | CN¥2.08 Billion |
|
Robo.ai Inc.
NASDAQ:AIIO
|
USA | $104.16 Million |
|
Jacquet Metal Service SA
PA:JCQ
|
France | €786.00 Million |
|
Five Point Holdings LLC
NYSE:FPH
|
USA | $810.04 Million |
|
ENF Technology Co. Ltd
KQ:102710
|
Korea | ₩286.91 Billion |
|
LH Shopping Centers Leasehold
BK:LHSC
|
Thailand | ฿3.94 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Larimar Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Larimar Therapeutics Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Larimar Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Larimar Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Larimar Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $67.76 Million | +138.47% |
| 2024-12-31 | $28.41 Million | +99.88% |
| 2023-12-31 | $14.21 Million | -8.30% |
| 2022-12-31 | $15.50 Million | +8.76% |
| 2021-12-31 | $14.25 Million | -4.94% |
| 2020-12-31 | $14.99 Million | +154.35% |
| 2019-12-31 | $5.89 Million | -79.31% |
| 2018-12-31 | $28.49 Million | +4.39% |
| 2017-12-31 | $27.29 Million | +175.85% |
| 2016-12-31 | $9.89 Million | -50.52% |
| 2015-12-31 | $20.00 Million | +52.90% |
| 2014-12-31 | $13.08 Million | +348.64% |
| 2013-12-31 | $2.92 Million | -0.51% |
| 2012-12-31 | $2.93 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.